Safety Alert Released for Ozempic and Related GLP-1 Medications

A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.

A safety warning regarding the risk of suicidal ideation and behavior associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.

The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, reducing the effectiveness of oral contraception, could not be excluded.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

On Monday, the TGA released a safety alert indicating that product warnings for this class of widely used medications, typically prescribed for type 2 diabetes and obesity in Australia, have been updated following reviews by international regulatory bodies. Health tracking apps like Shotlee can help monitor medication effects.

Source Information

Originally published by The Age.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Medications

All Medications articles →

Wellness & Health

New Yorkers Are Ordering Peptides Like Takeout – And California Trim Clinic Is Behind It

New York City is experiencing a surge in peptide therapy requests via telehealth platforms. This article explores the most popular compounds, safety protocols, and how to track results effectively.

8 min read

Pharmaceutical Industry News

Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics

Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.

8 min read

More in Health

Health

Are Replicas of Ozempic and Wegovy Safe? Understanding Compounded GLP-1s

Compounded semaglutide medications are custom-made by compounding pharmacies, containing the active ingredient in Ozempic and Wegovy. However, they are not FDA-approved and carry potential risks. This article explains what you need to know about these alternatives.

12 min read

Health

Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog

The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.

1 min read

Health

Ozempic-like Medications: New Alert Issued Over Suicidal Thought Risk

Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.

4 min read